Alport Syndrome News and Research

RSS
Alport syndrome is a genetic condition characterized by kidney disease, hearing loss, and eye abnormalities.
People with Alport syndrome experience progressive loss of kidney function. Almost all affected individuals have blood in their urine (hematuria), which indicates abnormal functioning of the kidneys. Many people with Alport syndrome also develop high levels of protein in their urine (proteinuria). The kidneys become less able to function as this condition progresses, resulting in end-stage renal disease (ESRD).
Scientists demonstrate an in vitro kidney model

Scientists demonstrate an in vitro kidney model

Disease-modifying therapy for Alport syndrome still remains an unmet need

Disease-modifying therapy for Alport syndrome still remains an unmet need

Study finds that several existing anti-cancer drugs may work in part by binding to RNA

Study finds that several existing anti-cancer drugs may work in part by binding to RNA

Novel screening tool aids search for curative kidney treatment

Novel screening tool aids search for curative kidney treatment

Extracellular vesicles can be used to effectively delay progression of kidney damage

Extracellular vesicles can be used to effectively delay progression of kidney damage

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus reports net loss of $7.2 million for fourth quarter 2015

Kumamoto University researchers identify protein that limits severity of Alport syndrome

Kumamoto University researchers identify protein that limits severity of Alport syndrome

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Scientists make human stem cells without working on human embryos

Scientists make human stem cells without working on human embryos

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Flaw in bone's material leads to disease

Flaw in bone's material leads to disease

Fibroid tumors lack crucial structural protein

Fibroid tumors lack crucial structural protein